Natural product-derived combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: Puerarin, isolated from Cucurbita texana, decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 3/January/2017, 11.53 am

What is known?

I have published earlier that Puerarin may suppress the expression of Tripeptidyl Peptidase 1 (TPP1) and Telomerase and inhibit cancer progression. 

---

From Research findings to Therapeutic opportunity: 

The study presented here suggests that Puerarin, by increasing the expression of its target genes, it may: (i) decrease the expression of Dihydropyrimidine dehydrogenase (DPYD); (ii) increase 5-FU accumulation in cancer cells; (iii) augment and restore chemosensitivity in drug-resistant Human cancers; (iv) promote anti-tumor effect; and (v) enhance the efficacy of anticancer drug treatment.

[easy_payment currency=”USD”]

Thereby, it may inhibit proliferation, chemoresistance and apoptosis of cancer cells. Thus, pharmacological formulations encompassing ” Puerarin or its analogue either alone or in combination with  5-FU, or any other anticancer drugs” may be used to inhibit cancer progression (Figs. 1-3).

Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Undisclosed information: How Puerarin decreases the expression of Dihydropyrimidine dehydrogenase (DPYD)?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $5

For purchase and payment details, you may reach us at info@genomediscovery.org

---

References: 

Citation: Boominathan, L., Natural product-derived combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: Puerarin, isolated from Cucurbita texana, decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 3/January/2017, 11.53 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org